Transcriptomic analyses reveal proinflammatory activation of human brain microvascular endothelial cells by

Yining Zhang1, Nina Karamanova2, Kaleb T Morrow2

  • 1Center for Personalized Diagnostics, Biodesign Institute, Arizona State University, Tempe, AZ, USA.

Scientific Reports
|November 2, 2023
PubMed

Insights

Medin peptide triggers inflammation in brain endothelial cells, contributing to vascular dementia and Alzheimer's disease. Nanoliposomes effectively reversed this medin-induced inflammation, offering a potential therapeutic strategy.

Area of Science:

  • Neuroscience
  • Vascular Biology
  • Molecular Biology

Background:

  • Medin is an amyloidogenic peptide linked to Alzheimer's disease (AD) and vascular dementia.
  • The specific pathology of medin in the brain vasculature is not fully understood.

Purpose of the Study:

  • To investigate transcriptomic changes in human brain microvascular endothelial cells (HBMVECs) exposed to medin.
  • To compare medin's effects with beta-amyloid (Aβ) exposure.
  • To evaluate the protective effects of monosialoganglioside-containing nanoliposomes (NL) against medin-induced changes.

Main Methods:

  • HBMVECs were treated with medin, Aβ(1-42), and/or NL.
  • RNA sequencing (RNA-seq) and signaling pathway analyses were performed.
  • Reverse transcription polymerase chain reaction (RT-PCR) was used to validate gene expression changes, including NFκB pathway involvement.

Main Results:

  • Medin upregulated pro-inflammatory genes in HBMVECs, an effect not worsened by co-treatment with Aβ42.
  • Pathway analysis identified significant activation of TNF and NFκB signaling by medin.
  • NL treatment reversed medin-induced pro-inflammatory gene expression and NFκB activation.

Conclusions:

  • Medin induces pro-inflammatory signaling in brain endothelial cells, partly through the NFκB pathway.
  • Nanoliposomes demonstrate a protective effect by reversing medin-induced inflammation.
  • These findings suggest potential therapeutic implications for vascular aging, AD, and vascular dementia.